M Marinova1, H M Strunk2, M Rauch2, J Henseler2, T Clarens2, L Brüx2, R Dolscheid-Pommerich3, R Conrad4, H Cuhls5, L Radbruch5, H H Schild2, M Mücke5,6. 1. Radiologische Klinik, Universitätsklinikum, Siegmund-Freud-Str. 25, 53105, Bonn, Deutschland. milka.marinova@ukb.uni-bonn.de. 2. Radiologische Klinik, Universitätsklinikum, Siegmund-Freud-Str. 25, 53105, Bonn, Deutschland. 3. Institut für Klinische Chemie und Pharmakologie, Universitätsklinikum, Bonn, Deutschland. 4. Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie, Universitätsklinikum, Bonn, Deutschland. 5. Klinik und Poliklinik für Palliativmedizin, Universitätsklinikum, Bonn, Deutschland. 6. Institut für Hausarztmedizin, Universitätsklinikum, Bonn, Deutschland.
Abstract
BACKGROUND: High-intensity focused ultrasound (HIFU) in combination with palliative standard therapy is an innovative and effective treatment option for pain reduction in patients with inoperable pancreatic cancer. OBJECTIVE: Evaluation of the effects of additive ultrasound (US)-guided HIFU treatment in inoperable pancreatic cancer on the sensory and affective pain perception using validated questionnaries. MATERIAL AND METHODS: In this study 20 patients with locally advanced inoperable pancreatic cancer and tumor-related pain were treated by US-guided HIFU (6 stage III, 12 stage IV according to UICC and 2 with local recurrence after surgery). Ablation was performed using the JC HIFU system (HAIFU, Chongqing, China) with an ultrasonic device for real-time imaging. Clinical assessment included evaluation of pain severity using validated questionnaires with particular attention to the pain sensation scale (SES) with its affective and sensory component and the numeric rating scale (NRS). RESULTS: The average pain reduction after HIFU was 2.87 points on the NRS scale and 57.3 % compared to the mean baseline score (n = 15, 75 %) in 19 of 20 treated patients. Four patients did not report pain relief, however, the previous opioid medication could be stopped (n = 2) or the analgesic dosage could be reduced (n = 2). No pain reduction was achieved in one patient. Furthermore, after HIFU emotional as well as sensory pain aspects were significantly reduced (before vs. 1 week after HIFU, p < 0.05 for all pain scales). CONCLUSION: US-guided HIFU can be used for effective and early pain relief and reduction of emotional and sensory pain sensation in patients with locally advanced pancreatic cancer.
BACKGROUND: High-intensity focused ultrasound (HIFU) in combination with palliative standard therapy is an innovative and effective treatment option for pain reduction in patients with inoperable pancreatic cancer. OBJECTIVE: Evaluation of the effects of additive ultrasound (US)-guided HIFU treatment in inoperable pancreatic cancer on the sensory and affective pain perception using validated questionnaries. MATERIAL AND METHODS: In this study 20 patients with locally advanced inoperable pancreatic cancer and tumor-related pain were treated by US-guided HIFU (6 stage III, 12 stage IV according to UICC and 2 with local recurrence after surgery). Ablation was performed using the JC HIFU system (HAIFU, Chongqing, China) with an ultrasonic device for real-time imaging. Clinical assessment included evaluation of pain severity using validated questionnaires with particular attention to the pain sensation scale (SES) with its affective and sensory component and the numeric rating scale (NRS). RESULTS: The average pain reduction after HIFU was 2.87 points on the NRS scale and 57.3 % compared to the mean baseline score (n = 15, 75 %) in 19 of 20 treated patients. Four patients did not report pain relief, however, the previous opioid medication could be stopped (n = 2) or the analgesic dosage could be reduced (n = 2). No pain reduction was achieved in one patient. Furthermore, after HIFU emotional as well as sensory pain aspects were significantly reduced (before vs. 1 week after HIFU, p < 0.05 for all pain scales). CONCLUSION: US-guided HIFU can be used for effective and early pain relief and reduction of emotional and sensory pain sensation in patients with locally advanced pancreatic cancer.
Authors: Franco Orsi; Lian Zhang; Paolo Arnone; Gianluigi Orgera; Guido Bonomo; Paolo Della Vigna; Lorenzo Monfardini; Kun Zhou; Wenzhi Chen; Zhibiao Wang; Umberto Veronesi Journal: AJR Am J Roentgenol Date: 2010-09 Impact factor: 3.959
Authors: H M Ceha; G van Tienhoven; D J Gouma; C H Veenhof; C J Schneider; E A Rauws; S S Phoa; D González González Journal: Cancer Date: 2000-12-01 Impact factor: 6.860
Authors: Zhenlin Hu; Xiao Yi Yang; Yunbo Liu; Georgy N Sankin; Eric C Pua; Michael A Morse; H Kim Lyerly; Timothy M Clay; Pei Zhong Journal: J Transl Med Date: 2007-07-11 Impact factor: 5.531
Authors: Dobromir Dimitrov; Holger M Strunk; Milka Marinova; Hyuliya Feradova; Maria A Gonzalez-Carmona; Rupert Conrad; Tolga Tonguc; Marcus Thudium; Marc U Becher; Zhou Kun; Grigor Gorchev; Slavcho Tomov; Christian P Strassburg; Ulrike Attenberger; Hans H Schild Journal: Eur Radiol Date: 2021-01-23 Impact factor: 5.315
Authors: Maxime Lafond; Thomas Lambin; Robert Andrew Drainville; Aurélien Dupré; Mathieu Pioche; David Melodelima; Cyril Lafon Journal: Cancers (Basel) Date: 2022-05-24 Impact factor: 6.575
Authors: Micah Belzberg; Smruti Mahapatra; Alexander Perdomo-Pantoja; Francisco Chavez; Kyle Morrison; Kah Timothy Xiong; Nao J Gamo; Stephen Restaino; Nitish Thakor; Youseph Yazdi; Rajiv Iyer; Betty Tyler; Nicholas Theodore; Mark G Luciano; Henry Brem; Mari Groves; Alan R Cohen; Amir Manbachi Journal: Ultrasonics Date: 2020-06-20 Impact factor: 2.890
Authors: Andrew L Coveler; Jonathan Mizrahi; Bory Eastman; Smith Jim Apisarnthanarax; Shalini Dalal; Terry McNearney; Shubham Pant Journal: Oncologist Date: 2021-05-12